Report cover image

Dog Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type, By Disease Type, By Route Of Administration, By Duration Of Immunity, By Component, By Region, And Segment Forecasts, 2023 - 2030

Publisher Grand View Research
Published Nov 20, 2023
Length 115 Pages
SKU # GV18388588

Description

Dog Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type, By Disease Type, By Route Of Administration, By Duration Of Immunity, By Component, By Region, And Segment Forecasts, 2023 - 2030


Dog Vaccine Market Growth & Trends

The global dog vaccine market size is anticipated to reach USD 2.6 billion by 2030 and display a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The growth can be attributed to the increasing trend of pet humanization, pet ownership among millennials, and rising consciousness regarding preventive healthcare. According to Boehringer Ingelheim International GmbH, 35% of millennials and 32% of baby boomers own a pet. In addition, the rise in pet spending and insurance is also expected to add to the growth of this market. According to an article published by WorldAnimalFoundation.org in February 2023, dog owners spent approximately USD 570 more than cat owners.

Moreover, the increasing pet population, rising income levels in emerging markets of Asia-Pacific, such as China and India, and consequent changes in the lifestyle of people are expected to impact the growth of the dog vaccine industry significantly. For instance, according to an article published by the Economic Times in July 2023, the per capita income in India is expected to increase by 1.6 times to reach USD 4000 by 2030.

Dog Vaccine Market Report Highlights
  • Based on vaccine type, the modified/attenuated live vaccine segment accounted for the largest revenue share of 52.4% in 2022, as they help prevent disease and provide long-term immunity
  • Based on disease type, the canine rabies segment is expected to grow at the fastest CAGR of 6.9% over the forecast period due to the high prevalence of this disease and its zoonotic potential
  • Based on route of administration, the injectable segment accounted for the largest revenue share of 76.1% in 2022, owing to their convenience and ability to administer accurate dosage amounts
  • Based on duration of immunity, the 1-year segment dominated the market with a share of 51.2% in 2022 owing to their convenience
  • Based on component, the combined vaccines segment accounted for the largest market share of 65.5%. It is expected to grow at the fastest CAGR of 6.2% over the forecast period due to its ability to protect against more than one disease
  • North America dominated with a share of 38.8% in 2022, owing to the presence of major players and increasing awareness regarding preventive healthcare for pets. On the other hand, Asia Pacific is anticipated to grow at the fastest CAGR of 7.0% over the forecast period due to untapped opportunities in the emerging economies of China and India
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

115 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Vaccine type
1.1.2. Disease type
1.1.3. Route of administration
1.1.4. Duration of immunity
1.1.5. Component
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Vaccine type outlook
2.2.2. Disease type outlook
2.2.3. Route of administration outlook
2.2.4. Duration of immunity outlook
2.2.5. Component outlook
2.2.6. Regional outlook
2.3. Competitive Insights
Chapter 3. Dog Vaccine Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Dog Vaccine Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Dog Vaccine: Vaccine Type Estimates & Trend Analysis
4.1. Dog Vaccine Market: Key Takeaways
4.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Modified/Attenuated Live
4.3.1. Modified/ attenuated live market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Inactivated (Killed)
4.4.1. Inactivated (Killed) market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Others
4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Dog Vaccine: Disease Type Estimates & Trend Analysis
5.1. Dog Vaccine Market: Key Takeaways
5.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Canine Distemper
5.3.1. Canine distemper market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Canine Infectious Respiratory Disease Complex (CIRDC)
5.4.1. Canine infectious respiratory disease complex (CIRDC) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Canine Parvovirosis/ Parvovirus Disease
5.5.1. Canine parvovirosis/ parvovirus disease market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Canine Leptospirosis
5.6.1. Canine leptospirosis market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Canine Lyme Disease
5.7.1. Canine lyme disease market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Infectious Canine Hepatitis
5.8.1. Infectious canine hepatitis market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Canine Rabies
5.9.1. Canine distemper market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Other Diseases
5.10.1. Other diseases market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Dog Vaccine: Route of Administration Estimates & Trend Analysis
6.1. Dog Vaccine Market: Key Takeaways
6.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Injectable
6.3.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Intranasal
6.4.1. Intranasal market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Oral
6.5.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Dog Vaccine: Duration of Immunity Estimates & Trend Analysis
7.1. Dog Vaccine Market: Key Takeaways
7.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
7.3. 1 Year
7.3.1. 1-year market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. 3 Year
7.4.1. 3-year market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Others
7.5.1. others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Dog Vaccine: Component Estimates & Trend Analysis
8.1. Dog Vaccine Market: Key Takeaways
8.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
8.3. Combined Vaccines
8.3.1. Combined vaccines market estimates and forecasts, 2018 to 2030 (USD Million)
8.4. Mono Vaccines
8.4.1. Mono vaccines market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Dog Vaccine Market: Regional Estimates & Trend Analysis
9.1. Regional Outlook
9.2. Dog Vaccine Market by Region: Key Takeaways
9.3. North America
9.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.3.2. U.S.
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework/reimbursement structure
9.3.2.3. Competitive scenario
9.3.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.3.3. Canada
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework/reimbursement structure
9.3.3.3. Competitive scenario
9.3.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4. Europe
9.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.2. UK
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework/reimbursement structure
9.4.2.3. Competitive scenario
9.4.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.3. Germany
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework/reimbursement structure
9.4.3.3. Competitive scenario
9.4.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.4. France
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework/reimbursement structure
9.4.4.3. Competitive scenario
9.4.4.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.5. Italy
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework/reimbursement structure
9.4.5.3. Competitive scenario
9.4.5.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.6. Spain
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework/reimbursement structure
9.4.6.3. Competitive scenario
9.4.6.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.7. Denmark
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework/reimbursement structure
9.4.7.3. Competitive scenario
9.4.7.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.8. Sweden
9.4.8.1. Key country dynamics
9.4.8.2. Regulatory framework/reimbursement structure
9.4.8.3. Competitive scenario
9.4.8.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.9. Norway
9.4.9.1. Key country dynamics
9.4.9.2. Regulatory framework/reimbursement structure
9.4.9.3. Competitive scenario
9.4.9.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5. Asia Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.2. China
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.3. India
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework/reimbursement structure
9.5.3.3. Competitive scenario
9.5.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.4. Australia
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework/reimbursement structure
9.5.4.3. Competitive scenario
9.5.4.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.5. Thailand
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework/reimbursement structure
9.5.5.3. Competitive scenario
9.5.5.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.6. South Korea
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework/reimbursement structure
9.5.6.3. Competitive scenario
9.5.6.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.6.2. Mexico
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.6.3. Argentina
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework/reimbursement structure
9.6.3.3. Competitive scenario
9.6.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.7. MEA
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Market Participant Categorization
10.2.1. Bioveta, a.s.
10.2.1.1. Company overview
10.2.1.2. Financial performance
10.2.1.3. Product benchmarking
10.2.1.4. Strategic initiatives
10.2.2. HESTER BIOSCIENCES LIMITED
10.2.2.1. Company overview
10.2.2.2. Financial performance
10.2.2.3. Product benchmarking
10.2.2.4. Strategic initiatives
10.2.3. Boehringer Ingelheim International GmbH
10.2.3.1. Company overview
10.2.3.2. Financial performance
10.2.3.3. Product benchmarking
10.2.3.4. Strategic initiatives
10.2.4. Brilliant Bio Pharma
10.2.4.1. Company overview
10.2.4.2. Financial performance
10.2.4.3. Product benchmarking
10.2.4.4. Strategic initiatives
10.2.5. Heska Corporation
10.2.5.1. Company overview
10.2.5.2. Financial performance
10.2.5.3. Product benchmarking
10.2.5.4. Strategic initiatives
10.2.6. Merck & Co., Inc.
10.2.6.1. Company overview
10.2.6.2. Financial performance
10.2.6.3. Product benchmarking
10.2.6.4. Strategic initiatives
10.2.7. Virbac
10.2.7.1. Company overview
10.2.7.2. Financial performance
10.2.7.3. Product benchmarking
10.2.7.4. Strategic initiatives
10.2.8. Zendal group
10.2.8.1. Company overview
10.2.8.2. Financial performance
10.2.8.3. Product benchmarking
10.2.8.4. Strategic initiatives
10.2.9. Elanco
10.2.9.1. Company overview
10.2.9.2. Financial performance
10.2.9.3. Product benchmarking
10.2.9.4. Strategic initiatives
10.2.10. Zoetis Services LLC
10.2.10.1. Company overview
10.2.10.2. Financial performance
10.2.10.3. Product benchmarking
10.2.10.4. Strategic initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us